PLUS1
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Salvarx Grp | LSE:SALV | London | Ordinary Share | IM00BZ4SS228 | ORD 2.5P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.25p | +3.78% | 61.75p | 59.00p | 64.50p | - | - | - | 536 | 16:35:05 |
| Industry Sector | Turnover (m) | Profit (m) | EPS - Basic | PE Ratio | Market Cap (m) |
|---|---|---|---|---|---|
| Health Care Equipment & Services | 0.0 | -2.8 | -0.1 | - | 22.56 |
SalvaRx Group plc Delay in iOx development programme
23/07/2018 1:17pm
UK Regulatory (RNS & others)
Salvarx Grp (LSE:SALV)
Historical Stock Chart
6 Months : From May 2018 to Nov 2018
TIDMSALV
RNS Number : 4740V
SalvaRx Group plc
23 July 2018
SalvaRx Group plc
("SalvaRx" or the "Company")
Delay to iOx development programme
SalvaRx (LON: SALV), a biotechnology company focused on immunotherapy for cancer, announces that its 57% owned subsidiary, iOx Therapeutics Limited ("iOx"), has experienced a significant delay in manufacturing its lead drug candidate IMM60.
Due to quality failures in the manufacturing process that led to a batch failure, iOx is revising its timeline to dosing its first human in clinical trials. The company is confident that its process is robust and that it will move the programme forward in due course. Release of the product required for the initiation of human dosing is now likely to be in late 2019.
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.
-Ends-
SalvaRx Group plc Ian Walters (Chief Executive) Tel: +1 203 441 5451 Northland Capital Partners Limited Tel: +44 (0) 20 3861 Nominated Adviser and Broker 6625 Matthew Johnson / Edward Hutton (Corporate Finance) Vadim Alexandre (Corporate Broking) Peterhouse Corporate Finance Limited Tel: +44 (0) 20 7469 Joint Broker 0932 Lucy Williams / Duncan Vasey
For more information please visit: www.salvarx.io
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
MSCUOAURWSABUAR
(END) Dow Jones Newswires
July 23, 2018 08:17 ET (12:17 GMT)
1 Year Salvarx Grp Chart |
1 Month Salvarx Grp Chart |
